APT(SH:688617) Sou Hu Cai Jing·2025-11-14 00:33Core Viewpoint - Huatai Medical (688617) experienced a decline of 2.15% in stock price, closing at 279.0 yuan on November 13, 2025, with a trading volume of 6,989 hands and a turnover of 196 million yuan [1]. Fund Flow Summary - On November 13, 2025, the net outflow of main funds was 1.27 million yuan, accounting for 0.65% of the total turnover, while retail funds saw a net inflow of 2.80 million yuan, representing 1.43% of the total turnover [1][2]. - Over the past five days, the stock has shown fluctuating fund flows, with significant net outflows from main funds on several days, particularly on November 10, where the outflow reached 15.36 million yuan [2]. Financing and Margin Trading Data - On November 13, 2025, the financing balance was 151 million yuan, with a net financing purchase of 5.35 million yuan. The margin trading balance stood at 168 million yuan [3]. - The stock's margin trading data indicates a consistent level of activity, with a total of 6,100 shares remaining in the margin account as of November 13, 2025 [3]. Company Performance Metrics - Huatai Medical's market capitalization is 39.34 billion yuan, ranking 4th in the medical device industry, while its net profit of 623 million yuan places it 9th in the same sector [4]. - The company reported a year-on-year revenue increase of 22.47% for the first three quarters of 2025, with a net profit growth of 18.02% [4]. - The gross profit margin stands at 73.19%, significantly higher than the industry average of 51.22%, indicating strong operational efficiency [4]. Institutional Ratings - In the last 90 days, 14 institutions have rated Huatai Medical, with 12 buy ratings and 2 hold ratings, suggesting a positive outlook among analysts [5]. - The average target price set by institutions over the past 90 days is 363.54 yuan, indicating potential upside from the current trading price [5].